GRI Bio Advances in IPF Treatment with Promising Trial Results

Gri Bio, Inc. ( (GRI) ) has released its Q1 earnings. Here is a breakdown of the information Gri Bio, Inc. presented to its investors.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting Natural Killer T cells to treat inflammatory, fibrotic, and autoimmune diseases.

In its latest financial report, GRI Bio announced its first-quarter 2025 results, highlighting progress in its Phase 2a trial for GRI-0621, a treatment for Idiopathic Pulmonary Fibrosis (IPF). The company also reported a successful public offering that extended its cash runway through the third quarter of 2025.

Key financial metrics included a net loss of $3.0 million for the quarter, with research and development expenses rising to $1.6 million. The company completed patient enrollment for a 6-week interim analysis in its ongoing trial and reported positive interim safety and biomarker results, suggesting an anti-fibrotic effect of GRI-0621.

Additionally, GRI Bio strengthened its intellectual property portfolio with new patents in Europe and Japan and announced its participation in the 2025 American Thoracic Society International Conference.

Looking ahead, GRI Bio remains focused on advancing its clinical programs, with upcoming milestones including the release of 6-week interim results and topline data from its Phase 2a study later this year. The company is optimistic about building long-term value for shareholders and addressing unmet needs in IPF treatment.